Author

Kinaya Smith

Institution: Medical College of Wisconsin

Observed institution: Medical College of Wisconsin

OpenAlex ID: A5113114544

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

2024 · Surbhi Sidana, Krina K. Patel, et al. · Blood · 152

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

2025 · Doris K. Hansen, Lauren C. Peres, et al. · Journal of Clinical Oncology · 54

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

2024 · Doris K. Hansen, Lauren C. Peres, et al. · Blood · 3

P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience

2023 · Surbhi Sidana, Krina Patel, et al. · Clinical Lymphoma Myeloma & Leukemia · 3

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

2025 · Doris K. Hansen, Lauren C. Peres, et al. · Journal of Clinical Oncology · 2

Ciltacabtagene Vicluecel (Cilta-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

2025 · Surbhi Sidana, Lauren C Peres, et al. · Transplantation and Cellular Therapy · 2

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

2024 · Lauren C. Peres, Alicia Richards, et al. · Blood · 2

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

2024 · Cindy Varga, Myra Robinson, et al. · Blood · 2

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

2025 · Akriti Jain, Umar Iqbal, et al. · Blood · 1

OA-11 Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up

2024 · Surbhi Sidana, Krina Patel, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

PB1791 The “Abnormal” Flag Matters: Improving Identification and Treatment of Iron Deficiency in Females by Removing Sex Differences in Ferritin Normal Range

2026 · Lisa Baumann Kreuziger, Jessica Kent, et al. · Research and Practice in Thrombosis and Haemostasis

CML-929: Validation of a Prognostic Score in Blast-Phase CML: A Cure CML Consortium Analysis

2026 · Akriti Jain, Zhuoer Xie, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: CML-929: Validation of a Prognostic Score in Blast-Phase CML: A Cure CML Consortium Analysis

2026 · Akriti Jain, Zhuoer Xie, et al. · Clinical Lymphoma Myeloma & Leukemia

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

2024 · Akriti G. Jain, Kinaya Smith, et al. · Blood

Infectious and Non-Infectious Pulmonary Complications in HCT Patients Treated with Post Transplant Cyclophosphamide (PTCy) Based Gvhd Prophylaxis

2024 · Skyler Taylor, Na Hyun Kim, et al. · Transplantation and Cellular Therapy

Infectious and Non-Infectious Pulmonary Complications in HCT Patients Treated with Post Transplant Cyclophosphamide (PTCy) Based Gvhd Prophylaxis

2023 · Skyler Taylor, Annie Kim, et al. · Blood

Works count: 16

Citation count: 222

H-index: 3

I10-index: 2